Endo to buy Indevus in deal worth up to $637 million
The year is less than a week old and the drugs sector’s first merger has been announced – Endo Pharmaceutical is to acquire Indevus.
Read MoreAuthor: Kevin Grogan
Adolf Merckle, head of Phoenix and Ratiopharm, kills himself
German billionaire Adolf Merckle, whose 120-firm conglomerate includes the drugs wholesaler Phoenix and the generics major Ratiopharm, has committed suicide, weighed down by the battle to keep his family’s businesses afloat.
Read MoreUCB stock down as FDA asks for more Cimzia data
UCB has suffered a major blow with the news that US regulators have asked for more safety data on the Belgian drugmaker’s anti-tumour necrosis factor agent Cimzia as a treatment for rheumatoid arthritis.
Read MoreNICE to expand use of life-extending drugs for terminally-ill
The UK’s drug cost-effectiveness watchdog has announced plans to improve access to treatments “which may extend life, at the end of life”.
Read MoreFebruary 3 will be D-day for Lilly/Daiichi’s prasugrel
Regulators in the USA have set a date to review Eli Lilly and Daiichi Sankyo’s highly-anticipated bloodthinner prasugrel, which should finally lead to a decision on whether the drug should be approved.
Read More- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
